Minimally invasive segmentectomy versus lobectomy for stage I lung cancer: recovery and quality of life
Living After Lung Surgery: Clinical Outcomes and Quality Of Life After Minimally Invasive Segmentectomy Versus Lobectomy for Lung Cancer
This test sees if people with stage I non-small cell lung cancer who have minimally invasive segmentectomy have less breathlessness and better quality of life in the first year after surgery than those who have lobectomy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 180 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal Academic / other |
| Locations | 1 site (Madrid, Madrid) |
| Trial ID | NCT07477158 on ClinicalTrials.gov |
What this trial studies
This is an observational study collecting patient-reported outcomes before surgery and at multiple points during the first year after minimally invasive segmentectomy or lobectomy for stage I NSCLC. Participants complete questionnaires on dyspnea, physical function, and health-related quality of life, and outcomes after video-assisted (VATS) versus robotic-assisted (RATS) approaches are compared. Patients with recent thoracic surgery, neoadjuvant therapy, or who fail to complete baseline questionnaires are excluded. The study is conducted at Hospital Universitario Ramón y Cajal in Madrid and uses routine surgical care rather than experimental interventions.
Who should consider this trial
Good fit: Adults with clinical stage I non-small cell lung cancer who are undergoing minimally invasive segmentectomy or lobectomy (VATS or RATS), have not had thoracic surgery in the past year, and have not received neoadjuvant therapy are the ideal candidates.
Not a fit: Patients with more advanced or unresectable disease, recent thoracic surgery, prior neoadjuvant therapy, or those unable to complete the required questionnaires are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, the findings could show that segmentectomy preserves breathing function and quality of life better than lobectomy, helping clinicians and patients choose a less disruptive operation when oncologically appropriate.
How similar studies have performed: Randomized trials (for example JCOG0802) have shown segmentectomy can preserve lung function and have comparable oncologic outcomes for small peripheral NSCLC, but focused patient-reported outcome comparisons remain limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with clinical stage I NSCLC who undergo segmentectomy or lobectomy with VATS or RATS. Exclusion Criteria: * Thoracic surgery in the previous year * Neoadyuvant treatment * Failure to complete preoperative questionnaires
Where this trial is running
Madrid, Madrid
- Hospital Universitario Ramón y Cajal — Madrid, Madrid, Spain (Recruiting)
Study contacts
- Principal investigator: Sara Fra, MD — Hospital Universitario Ramón y Cajal
- Study coordinator: Sara Fra, MD
- Email: sarafrafernandez@gmail.com
- Phone: 0034913369102
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.